| 268 | 3 | 28 |
| 下载次数 | 被引频次 | 阅读次数 |
目的筛选及优化莫匹罗星微乳经皮给药系统。方法采用HPLC方法测定莫匹罗星在各辅料中的饱和溶解度和绘制伪三元相图,确定微乳处方所用辅料及Km值。以粒径、稳定性及皮肤滞留量为考察指标,通过星点设计-效应面法优化微乳制剂处方。结果经过处方筛选及优化,确定莫匹罗星微乳最优处方为:20.3%MAISINE 35-1、13.23%吐温80、13.23%LABRASOL、26.46%TRANSCUTOLP和26.78%水。微乳粒径均匀,稳定性较好,皮肤滞留量为(45.07±2.03)mg·g-1,符合透皮微乳要求。结论本实验制得了符合要求的莫匹罗星微乳,为进一步研究奠定了良好的基础。
Abstract：AIM To screen and optimize the formulation of mupirocin microemulsion transdermal delivery system.METHODS Mupirocin use as indexes,its saturated solubility in various materials was determined by HPLC and initially identified several materials in which mupirocin's solubility was greater.Then pseudo-ternary phase diagrams were drawn and primary compositions and Km values of microemulsion formulation according to the area of microemulsion in phase diagrams were obtained.Finally,the formulation was optimized by central composite design and its quality indexes including particle size,stability and the amount of mupirocin retention in the skin were determined.RESULTS After screening and optimization,the optimal mupirocin microemulsion formulation was:20.3%MAISINE 35-1,13.23%Tween 80,13.23%LABRASOL,26.46%TRANSCUTOL P and 26.78%water.The microemulsion equipped with uniform particle size,good stability and retention amount[(45.07 ±2.03) mg·g-1]in skin was accorded with the requirement of transdermal microemuslion.CONCLUSION The optimal mupirocin microemulsion has the characteristics of uniform particle size,good stability and retention amount,which provides a good foundation for further study.
[1]Fuller AT,Mellows G,Woolford M,et al.Pseudomonic acid:an antibiotic produced by Pseudomonas fluorescens[J].Nature,1971,234(5329):416.
[2]陈申.莫匹罗星(百多邦):全新的外用抗生素—对多种抗生素耐药的细菌有效[J].临床外科杂志,1996,4(4):233.
[3]王富军.莫匹罗星的药理作用及细菌耐药性[G]∥中国中西医结合学会皮肤性病专业委员会.全国中西医结合皮肤性病学术会议论文汇编.北京:中国中西医结合学会,2008:8.
[4]Dorrani M,Kaul M,Parhi A,et al.TXA497 as a topical antibacterial agent:comparative antistaphylococcal,skin deposition,and skin permeation studies with mupirocin[J].Int J Pharm,2014,476(1-2):199.
[5]Echevarr AL,Blanco-Pr Eto MAJ,Campanero MA,et al.Development and validation of a liquid chromatographic method for in vitro mupirocin quantification in both skin layers and percutaneous penetration studies[J].J Chromatogr B Analyt Technol Biomed Ufe Sci,2003,796(2):233.
[6]Zhao L,Wang Y,Zhai Y,et al.Ropivacaine loaded microemulsion and microemulsion-based gel for transdermal delivery:preparation,optimization,and evaluation[J].Int J Pharm,2014,477(1-2):47.
[7]马俐丽,朱照静,匡扶,等.普罗布考自微乳释药系统处方优化及体内外评价[J].中国药科大学学报,2009,40(1):41.
[8]Hathout RM,Nasr M.Transdermal delivery of betahistine hydrochloride using microemulsions:physical characterization,biophysical assessment,confocal imaging and permeation studies[J].Colloids Surf B Biointerfaces,20I3,110:254.
[9]朱晓亮.陈志良,曾抗,等.微乳透皮给药系统研究现状及展望(J).广东医学,2005,26(4):563.
[10]刘彩艳,宋英.微乳透皮给药系统的研究进展[J].中药与临床,2014,5(1):57.
[11]Abioye AO,Issah S,Kola-Mustapha AT.Ex vivo skin pemieation and retention studies on chitosan-ibuprofen-gellan ternary nanogel prepared by in situ ionic gelation technique—a tool for controlled transdermal delivery of ibuprofen[J].Int J Pharm,2015,490(1-2):112.
[12]Lucca LG,de Matos SP,Borille BT,et al.Determination of betacaryophyllene skin permeation/retention from crude copaiba oil(Copaifera multijuga Hayne)and respective oil-based nanoemulsion using a novel HS-GC/MS method[J].J Pharm Biomed Anal,2015,104:144.
[13]王学川,邱白玉.表面活性剂的毒性问题[J].日用化学品科学,2005,28(6):22.
[14]Al Abood RM,Talegaonkar S,Tariq M,et al.Microemulsion as a tool for the transdermal delivery of ondansetron for the treatment of chemotherapy induced nausea and vomiting[J].Colloids Surf B Biointerfaces,2013,101:143.
[15]Zhao X,Liu JP,Zhang X,et al.Enhancement of transdermal delivery of theophylline using microemulsion vehicle[J].Int J Pharmaceut,2006,327(1-2):58.
[16]Warisnoicharoen W,Lansley AB,Lawrence MJ.Light scattering investigations on dilute nonionic oil-in-water microemulsions[J].AAPS PharmSci,2000,2(2):E12.
[17]Hathout RM,Elshafeey AH.Development and characterization of colloidal soft nano-carriers for transdermal delivery and bioavailability enhancement of an angiotensin II receptor blocker[J].Eur J Pharm Biopharm,2012,82(2):230.
基本信息:
DOI：10.19577/j.cnki.issn10074406.2016.06.001
中图分类号:R91
引用信息:
[1]孟林,王晓飞,沙先谊,等.星点设计-效应面法优化莫匹罗星微乳透皮给药系统[J].中国临床药学杂志,2016,25(06):333-338.DOI:10.19577/j.cnki.issn10074406.2016.06.001.
基金信息:
【基金项目】符合GLP要求的新剂型与新释药系统技术平台建设(编号2012ZX09304004)
2016-01-25
2016
2016-05-12
2016-06-02
2016
1
2016-11-25
2016-11-25